(RTTNews) - Biogen Inc. (BIIB) announced Wednesday the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results